Company Profile
CRISPR Therapeutics Stock Price, News & Analysis
Company overview
Business overview
CRISPR Therapeutics is a gene-editing company with exposure to cell therapy and genetic medicine. Investors watch the company for how its editing platform broadens beyond the first commercial and clinical milestones.
Geographic Base and Sector Classification
Headquartered in Zug, Switzerland and listed on NASDAQ, CRISPR Therapeutics is followed within the gene-editing universe for its platform risk, clinical milestones, and commercial expansion potential.
Business Model Characteristics
CRISPR Therapeutics follows a platform-led model where proof of editing performance, regulatory progress, and partner execution shape the investment case.
Position Within the Biotechnology Landscape
Compared with more mature biotech peers, CRISPR Therapeutics sits near the high-catalyst end of the landscape, where each major update can move the stock sharply.
Why the stock is moving
CRSP is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
CRISPR Therapeutics's catalysts are Casgevy rollout in sickle cell and beta-thalassemia, plus the in vivo CTX310 and CTX340 programs that show whether the platform can create a second growth curve. The next three months matter because the market still wants proof that exa-cel can scale while the newer editing programs keep de-risking the story.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Source: CRISPR Therapeutics
- 02
- 03
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Source: CRISPR Therapeutics
- 04
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
Source: CRISPR Therapeutics
- 05
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Source: CRISPR Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.